Atxilox® is a polyherbal formulation exhibiting varying mechanism of action. First, Atxilox® inhibits The Mammalian Target of Rapamycin (mTOR) kinase.
mTOR controls cell growth, proliferation and energy metabolism (Reprogramming Energy Metabolism).3 Therefore, inhibiting mTOR leads to cell cycle arrest and metabolic starvation. Secondly, Atxilox® acts as VEGFR kinase inhibitor which blocks oncogenic angiogenesis, also, weak dual BRAF inhibitors with MEK inhibitory actions have been demonstrated in , Atxilox®.
MyoFibrox® is a polyherbal formulation exhibiting combinatorial mechanism of action aimed at reducing uterine size. First, MyoFibrox ® weakly inhibits nuclear receptor subfamily 3, group C, member 3 (progesterone receptor) and estrogen receptor (ER).
Prostafexin® is a polyherbal formulation exhibiting combinatorial mechanism of action aimed at reducing prostate size. First, Prostafexin® specifically inhibits prostate 5α-reductase type 2.
Metaxin® modulates Epithelial-Mesenchymal Transition (EMT), whereas tumour cells loose adhesion to the primary tumor and extracellular matrix (ECM) promoted by proteolytic degradation of the ECM by enzymes like matrix metalloproteinases (MMPs); and the activation of signaling pathways that promote cell motility and survival. Broadly, Metaxin® has two mechanisms of action.
